Is silence misconduct, page-162

Anyways, putting aside the questions on the science & selling and buying, the history of the company is also v.fascinating. It certainly started in a less than ideal fashion, judging by the claims against company.

Not sure anyone looked at the old AFR article, I linked in a previous post (some s/s attached). But in a nutshell....

"Two academics from a prestigious Australian medical research centres are clashing over a prospectus claim. The issue involves the float on 24 January of Biotron, a medical research company, founded by John Curtin School of Medical Research (JCSMR) professor, Peter Gage. Biotron's prospectus, used to raise $A12 million, refers to the development of anti-viral agents to block ion channels that carry viruses, such as those causing dengue and Ross River fevers. Fellow JCSMR professor, Graeme Laver, from the institute's biochemistry and molecular biology division, has complained to the Australian Securities and Investments Commission that there is no proof these particular viruses possess ion channels ".

The prospectus -http://www.biotron.com.au/wp-content/uploads/2013/04/Biotron_assirt_review.pdf

We know that the complaints were dismissed by the regulators, because it did not contavene ASIC guidelines but was Laver right or wrong about the Ion exchange.

What ever happened to Ross River and dengue testing? (we know they plan to come back to dengue at some point).

Interesting further commentary

https://www.google.com/url?q=https:...00&usg=AFQjCNFRafqLn-vTU9d5OdmmsPzV9NGmHA

"ANU failed to have the science reviewed to any meaningful extent. The ANU should have insisted that the science that it is backing in Biotron be peer reviewed with the same rigor as is necessary to obtain funding from the National Health and Medical Research Council or the Australian Research Council".

holder or non holder. We all have the right to discuss this fascinating stock. Unfortunately judging by the number of failed bios on the asx, this is an area that needs more regulatory focus and maybe specific bio stock disclosure rules.